<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02743377</url>
  </required_header>
  <id_info>
    <org_study_id>160093</org_study_id>
    <secondary_id>16-M-0093</secondary_id>
    <nct_id>NCT02743377</nct_id>
  </id_info>
  <brief_title>PET Imaging of Phosphodiesterase-4 (PDE4) in Brain and Peripheral Organs of McCune-Albright Syndrome</brief_title>
  <official_title>PET Imaging of Phosphodiesterase-4 (PDE4) in Brain and Peripheral Organs of Mccune-Albright Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      McCune-Albright Syndrome (MAS) is a disorder that affects the bones, skin, and some&#xD;
      hormone-producing tissues. It is associated with a mutation in a gene. This gene affects&#xD;
      enzymes in the brain and body. Researchers want to learn more about one of these enzymes,&#xD;
      Phosphodiesterase 4 (PDE4), in people with MAS.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      To see if people with MAS have higher levels of PDE4 than people without MAS.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      People ages 18 and older who have MAS and participated in protocol 98-D-0145, Screening and&#xD;
      Natural History of Patients with Polyostotic Fibrous Dysplasia and the McCune-Albright&#xD;
      Syndrome. Healthy adult volunteers are also needed.&#xD;
&#xD;
      Design:&#xD;
&#xD;
      This study requires 1 to 4 outpatient visits to the NIH Clinical Center. Some visits may take&#xD;
      place on the same day.&#xD;
&#xD;
      Participants with MAS will be screened with medical history and physical exam. They will have&#xD;
      blood and urine tests.&#xD;
&#xD;
      Participants will have a magnetic resonance imaging scan.&#xD;
&#xD;
      Participants will have a full body positron emission tomography (PET) scan. A small amount of&#xD;
      a radioactive chemical, [11C](R)-rolipram, will be given through an intravenous tube.&#xD;
&#xD;
      Participants will have a brain PET scan with [11C](R)-rolipram. For this, a thin plastic tube&#xD;
      will also be put into an artery at their wrist or elbow crease area.&#xD;
&#xD;
      For the scans, participants will lie on a bed that slides in and out of a scanner. They may&#xD;
      wear a plastic mask to hold their head in place. They will have blood drawn.&#xD;
&#xD;
      Participants with MAS will be interviewed about their thinking and mood. They may complete&#xD;
      questionnaires about how they feel or think.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: McCune-Albright syndrome (MAS) is a mosaic disease arising from early embryonic&#xD;
      somatic activating mutations of GNAS, which encodes the 3 &lt;=, 5 &lt;=-cyclic adenosine&#xD;
      monophosphate (cAMP) pathway-associated G-protein, Gs . Constitutive activation of Gs leads&#xD;
      to increased cAMP signaling in brain, as well as in peripheral organs, particularly bones.&#xD;
      Although subjects with MAS show psychiatric and neurological symptoms, few studies have&#xD;
      attempted to assess brain changes in these individuals. This protocol seeks to study changes&#xD;
      in the cAMP cascade both in brain and peripheral organs of individuals with MAS using&#xD;
      [11C](R)-rolipram PET, which binds to phosphodiesterase 4 (PDE4) and reflects cAMP cascade&#xD;
      activity.&#xD;
&#xD;
      Study population: Participants will include 20 subjects with MAS and 15 healthy subjects&#xD;
      group-matched to MAS subjects for age and gender. Both MAS subjects and healthy controls will&#xD;
      have one or two PET scans: one whole body and one brain scan. We expect about 10 brain and 10&#xD;
      whole body scan to be performed in each group.&#xD;
&#xD;
      Design: Subjects with MAS will be recruited from participants in 98-D-0145 Screening and&#xD;
      Natural History of Patients with Polyostotic Fibrous Dysplasia and the McCune-Albright&#xD;
      Syndrome (PI: Alison M. Boyce, MD). Only participants in protocol (98-D-0145) who provided&#xD;
      self-consent without a legally authorized representative will be recruited. Brain PET scans&#xD;
      will be performed by measuring metabolite-corrected arterial input function. No venous blood&#xD;
      sampling will be performed for whole body scans.&#xD;
&#xD;
      Outcome measures: The primary outcome measure will be obtained in brain scans as the amount&#xD;
      of radioligand binding quantified as distribution volume (Vt). Calculated from both brain and&#xD;
      plasma data, Vt reflects rolipram binding to PDE4, corrected for any individual differences&#xD;
      in metabolism of the radioligand or regional blood flow in brain. The secondary outcome&#xD;
      measure will be obtained in whole body scans as area under the curve (AUC) of radioactivity&#xD;
      expressed as standard uptake value (SUV). SUV is calculated by normalizing radioactivity in&#xD;
      PET images to injection activity and body weight. Vt in brain will be compared between&#xD;
      subjects with MAS and healthy controls. AUC will be compared within-subjects with MAS between&#xD;
      areas of craniofacial fibrous dysplasia and adjacent unaffected bone. AUC of whole body scans&#xD;
      will also be compared between subjects with MAS and healthy controls. We hypothesize that&#xD;
      subjects with MAS will show greater rolipram binding than healthy controls in brain regions,&#xD;
      as well as greater rolipram uptake in bones affected by fibrous dysplasia than in unaffected&#xD;
      bones.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 4, 2018</start_date>
  <completion_date type="Actual">May 19, 2020</completion_date>
  <primary_completion_date type="Actual">October 23, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) - Bladder</measure>
    <time_frame>120 minutes</time_frame>
    <description>Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) -Gallbladder</measure>
    <time_frame>120 minutes</time_frame>
    <description>Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) - Heart</measure>
    <time_frame>120 minutes</time_frame>
    <description>Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) - Kidneys</measure>
    <time_frame>120 minutes</time_frame>
    <description>Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) - Liver</measure>
    <time_frame>120 minutes</time_frame>
    <description>Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) - Lungs</measure>
    <time_frame>120 minutes</time_frame>
    <description>Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) -Spleen</measure>
    <time_frame>120 minutes</time_frame>
    <description>Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) - Stomach</measure>
    <time_frame>120 minutes</time_frame>
    <description>Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Whole Brain Total Distribution Volume (VT)</measure>
    <time_frame>90 minutes</time_frame>
    <description>Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the brain of patients with McCune-Albright Syndrome (MAS) compared to healthy controls</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MAS Affected Bone SUV AUC(60-120min) at Baseline</measure>
    <time_frame>120 minutes</time_frame>
    <description>To assess whether uptake in dysplastic bone reflects parent radioligand binding to the enzyme or merely accumulation of radiometabolites</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MAS Affected Bone SUV AUC(60-120min) - Blocked</measure>
    <time_frame>120 minutes</time_frame>
    <description>To assess whether uptake in dysplastic bone reflects parent radioligand binding to the enzyme or merely accumulation of radiometabolites</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MAS Affected Bone SUV AUC(60-120min) - for Baseline and Blocked Subjects With MAS</measure>
    <time_frame>120 minutes</time_frame>
    <description>Determine if PDE4 levels are different in areas of fibrous dysplasia as compared to unaffected bones in patients with MAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normal Bone SUV AUC (60-120min) - for Healthy Controls</measure>
    <time_frame>120 minutes after the start of the scan</time_frame>
    <description>Determine if PDE4 levels are different in areas of fibrous dysplasia as compared to unaffected bones in patients with MAS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Nervous System Disease</condition>
  <arm_group>
    <arm_group_label>Subjects with McCune-Albright syndrome (MAS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with McCune-Albright syndrome (MAS) who received 11C-(R)-rolipram whole-body and/or brain PET scans</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy control received 11C-(R)-rolipram whole-body and/or brain PET scans</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Brain PET Imaging with 11C Rolipram</intervention_name>
    <description>Brain PET Imaging, single scan, with 11C Rolipram 20 mCi given intravenously at the start of the scan</description>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_label>Subjects with McCune-Albright syndrome (MAS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Whole Body PET Baseline with 11C Rolipram</intervention_name>
    <description>Whole Body Baseline PET Imaging, single scan, with 11C Rolipram 20 mCi given intravenously at the start of the scan</description>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_label>Subjects with McCune-Albright syndrome (MAS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Whole Body PET Blocked with Roflumilast</intervention_name>
    <description>Whole Body PET Imaging scan after blockade with Roflumilast 500 mcg PO, given 1-2 hours prior to start of scan</description>
    <arm_group_label>Subjects with McCune-Albright syndrome (MAS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Subjects with MAS:&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Able to provide self-consent&#xD;
&#xD;
          -  Diagnosed with MAS under 98-D-0145.&#xD;
&#xD;
          -  Have craniofacial fibrous dysplasia&#xD;
&#xD;
        Healthy Subjects:&#xD;
&#xD;
          -  At least 18 years of age.&#xD;
&#xD;
          -  Healthy based on medical history and physical examination.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Subjects with MAS:&#xD;
&#xD;
          -  Serious medical conditions, which may interfere with study procedures. Such conditions&#xD;
             include but not limited to significant bone abnormalities in wrist areas of both arms,&#xD;
             which makes it difficult to place a radial arterial line, clinically marked&#xD;
             dysfunction of liver or kidney, which may delay clearance of [(11)C](R)-rolipram.&#xD;
&#xD;
          -  Clinically significant laboratory abnormalities not linked to endocrine abnormalities&#xD;
             but that may interfere with the PET measurement or affect safety of the participant&#xD;
             during this study.&#xD;
&#xD;
          -  Positive HIV test.&#xD;
&#xD;
          -  Head trauma resulting in a period of unconsciousness lasting longer than one hour.&#xD;
&#xD;
          -  Metallic foreign bodies that would be affected by the magnetic resonance imaging (MRI)&#xD;
             magnet, or fear of enclosed spaces likely to make the subject unable to undergo an MRI&#xD;
             scan.&#xD;
&#xD;
          -  Recent research-related exposure to radiation (i.e., PET from other research) that,&#xD;
             when combined with this study, would be above the allowable limits.&#xD;
&#xD;
          -  Inability to lie flat on camera bed for about two and a half hours.&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
&#xD;
          -  NIMH employees/staff and their immediate family members will be excluded from the&#xD;
             study per NIMH policy.&#xD;
&#xD;
        Healthy Subjects:&#xD;
&#xD;
          -  Serious medical conditions, which may interfere with study procedures. Such conditions&#xD;
             include but not limited to clinically marked dysfunction of liver or kidney, which may&#xD;
             delay clearance of [(11)C](R)-rolipram.&#xD;
&#xD;
          -  Clinically significant laboratory abnormalities that may interfere with the PET&#xD;
             measurement or affect safety of the participant during this study.&#xD;
&#xD;
          -  Personal history of any DSM Axis I disorder.&#xD;
&#xD;
          -  Positive HIV test.&#xD;
&#xD;
          -  Head trauma resulting in a period of unconsciousness lasting longer than one hour.&#xD;
&#xD;
          -  Metallic foreign bodies that would be affected by the MRI magnet, or fear of enclosed&#xD;
             spaces likely to make the subject unable to undergo an MRI scan.&#xD;
&#xD;
          -  Recent research-related exposure to radiation (i.e., PET from other research) that,&#xD;
             when combined with this study, would be above the allowable limits.&#xD;
&#xD;
          -  Inability to lie flat on camera bed for about two and a half hours.&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
&#xD;
          -  Current substance use disorder based on DSM.&#xD;
&#xD;
          -  NIMH employees/staff and their immediate family members will be excluded from the&#xD;
             study per NIMH policy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert B Innis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Mental Health (NIMH)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2016-M-0093.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <verification_date>May 19, 2020</verification_date>
  <study_first_submitted>April 15, 2016</study_first_submitted>
  <study_first_submitted_qc>April 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2016</study_first_posted>
  <results_first_submitted>September 24, 2020</results_first_submitted>
  <results_first_submitted_qc>September 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 19, 2020</results_first_posted>
  <last_update_submitted>September 24, 2020</last_update_submitted>
  <last_update_submitted_qc>September 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GsI+/-</keyword>
  <keyword>Camp</keyword>
  <keyword>GNAS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrous Dysplasia, Polyostotic</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rolipram</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 14, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT02743377/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>16 subjects were enrolled but one subject did not start the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Healthy Control</title>
          <description>Healthy controls received 11C-(R)-rolipram whole-body and/or brain PET scans</description>
        </group>
        <group group_id="P2">
          <title>Subjects With McCune-Albright Syndrome (MAS)</title>
          <description>Subjects with McCune-Albright syndrome (MAS) who received 11C-(R)-rolipram whole-body and/or brain PET scans</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Brain PET With 11C Rolipram</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Whole Body PET Baseline With 11C Rolipra</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Whole Body PET Baseline &amp; Blocked</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Healthy Control</title>
          <description>Healthy controls received 11C-(R)-rolipram whole-body and/or brain PET scans</description>
        </group>
        <group group_id="B2">
          <title>Subjects With McCune-Albright Syndrome (MAS)</title>
          <description>Subjects with McCune-Albright syndrome (MAS) who received 11C-(R)-rolipram whole-body and/or brain PET scans</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) - Bladder</title>
        <description>Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls.</description>
        <time_frame>120 minutes</time_frame>
        <population>Subjects who completed whole body scan with 11-C Rolipram</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Control</title>
            <description>Healthy control received 11C-(R)-rolipram whole-body and/or brain PET scans</description>
          </group>
          <group group_id="O2">
            <title>Subjects With McCune-Albright Syndrome (MAS)</title>
            <description>Subjects with McCune-Albright syndrome (MAS) who received 11C-(R)-rolipram whole-body and/or brain PET scans</description>
          </group>
        </group_list>
        <measure>
          <title>Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) - Bladder</title>
          <description>Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls.</description>
          <population>Subjects who completed whole body scan with 11-C Rolipram</population>
          <units>SUV x min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="575.1" spread="402.2"/>
                    <measurement group_id="O2" value="650.8" spread="344.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) -Gallbladder</title>
        <description>Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls.</description>
        <time_frame>120 minutes</time_frame>
        <population>Subjects who completed whole body scan with 11-C Rolipram</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Control</title>
            <description>Healthy control received 11C-(R)-rolipram whole-body and/or brain PET scans</description>
          </group>
          <group group_id="O2">
            <title>Subjects With McCune-Albright Syndrome (MAS)</title>
            <description>Subjects with McCune-Albright syndrome (MAS) who received 11C-(R)-rolipram whole-body and/or brain PET scans</description>
          </group>
        </group_list>
        <measure>
          <title>Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) -Gallbladder</title>
          <description>Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls.</description>
          <population>Subjects who completed whole body scan with 11-C Rolipram</population>
          <units>SUV x min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="581.2" spread="235.8"/>
                    <measurement group_id="O2" value="417.9" spread="317.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) - Heart</title>
        <description>Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls.</description>
        <time_frame>120 minutes</time_frame>
        <population>Subjects who completed whole body scan with 11-C Rolipram</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Control</title>
            <description>Healthy control received 11C-(R)-rolipram whole-body and/or brain PET scans</description>
          </group>
          <group group_id="O2">
            <title>Subjects With McCune-Albright Syndrome (MAS)</title>
            <description>Subjects with McCune-Albright syndrome (MAS) who received 11C-(R)-rolipram whole-body and/or brain PET scans</description>
          </group>
        </group_list>
        <measure>
          <title>Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) - Heart</title>
          <description>Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls.</description>
          <population>Subjects who completed whole body scan with 11-C Rolipram</population>
          <units>SUV x min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.4" spread="6.1"/>
                    <measurement group_id="O2" value="25.4" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) - Kidneys</title>
        <description>Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls.</description>
        <time_frame>120 minutes</time_frame>
        <population>Subjects who completed whole body scan with 11-C Rolipram</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Control</title>
            <description>Healthy control received 11C-(R)-rolipram whole-body and/or brain PET scans</description>
          </group>
          <group group_id="O2">
            <title>Subjects With McCune-Albright Syndrome (MAS)</title>
            <description>Subjects with McCune-Albright syndrome (MAS) who received 11C-(R)-rolipram whole-body and/or brain PET scans</description>
          </group>
        </group_list>
        <measure>
          <title>Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) - Kidneys</title>
          <description>Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls.</description>
          <population>Subjects who completed whole body scan with 11-C Rolipram</population>
          <units>SUV x min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.3" spread="14.8"/>
                    <measurement group_id="O2" value="80.4" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) - Liver</title>
        <description>Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls</description>
        <time_frame>120 minutes</time_frame>
        <population>Subjects who completed whole body scan with 11-C Rolipram</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Control</title>
            <description>Healthy control received 11C-(R)-rolipram whole-body and/or brain PET scans</description>
          </group>
          <group group_id="O2">
            <title>Subjects With McCune-Albright Syndrome (MAS)</title>
            <description>Subjects with McCune-Albright syndrome (MAS) who received 11C-(R)-rolipram whole-body and/or brain PET scans</description>
          </group>
        </group_list>
        <measure>
          <title>Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) - Liver</title>
          <description>Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls</description>
          <population>Subjects who completed whole body scan with 11-C Rolipram</population>
          <units>SUV x min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.6" spread="21.7"/>
                    <measurement group_id="O2" value="52.4" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) - Lungs</title>
        <description>Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls</description>
        <time_frame>120 minutes</time_frame>
        <population>Subjects who completed whole body scan with 11-C Rolipram</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Control</title>
            <description>Healthy control received 11C-(R)-rolipram whole-body and/or brain PET scans</description>
          </group>
          <group group_id="O2">
            <title>Subjects With McCune-Albright Syndrome (MAS)</title>
            <description>Subjects with McCune-Albright syndrome (MAS) who received 11C-(R)-rolipram whole-body and/or brain PET scans</description>
          </group>
        </group_list>
        <measure>
          <title>Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) - Lungs</title>
          <description>Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls</description>
          <population>Subjects who completed whole body scan with 11-C Rolipram</population>
          <units>SUV x min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" spread="4.3"/>
                    <measurement group_id="O2" value="9.6" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) -Spleen</title>
        <description>Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls</description>
        <time_frame>120 minutes</time_frame>
        <population>Subjects who completed whole body scan with 11-C Rolipram</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Control</title>
            <description>Healthy control received 11C-(R)-rolipram whole-body and/or brain PET scans</description>
          </group>
          <group group_id="O2">
            <title>Subjects With McCune-Albright Syndrome (MAS)</title>
            <description>Subjects with McCune-Albright syndrome (MAS) who received 11C-(R)-rolipram whole-body and/or brain PET scans</description>
          </group>
        </group_list>
        <measure>
          <title>Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) -Spleen</title>
          <description>Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls</description>
          <population>Subjects who completed whole body scan with 11-C Rolipram</population>
          <units>SUV x min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1" spread="2.8"/>
                    <measurement group_id="O2" value="18.7" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) - Stomach</title>
        <description>Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls</description>
        <time_frame>120 minutes</time_frame>
        <population>Subjects who completed whole body scan with 11-C Rolipram</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Control</title>
            <description>Healthy control received 11C-(R)-rolipram whole-body and/or brain PET scans</description>
          </group>
          <group group_id="O2">
            <title>Subjects With McCune-Albright Syndrome (MAS)</title>
            <description>Subjects with McCune-Albright syndrome (MAS) who received 11C-(R)-rolipram whole-body and/or brain PET scans</description>
          </group>
        </group_list>
        <measure>
          <title>Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) - Stomach</title>
          <description>Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls</description>
          <population>Subjects who completed whole body scan with 11-C Rolipram</population>
          <units>SUV x min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.4" spread="20.8"/>
                    <measurement group_id="O2" value="34.1" spread="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Whole Brain Total Distribution Volume (VT)</title>
        <description>Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the brain of patients with McCune-Albright Syndrome (MAS) compared to healthy controls</description>
        <time_frame>90 minutes</time_frame>
        <population>Subjects who completed brain scan with 11-C Rolipram</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Control</title>
            <description>Healthy control received 11C-(R)-rolipram whole-body and/or brain PET scans</description>
          </group>
          <group group_id="O2">
            <title>Subjects With McCune-Albright Syndrome (MAS)</title>
            <description>Subjects with McCune-Albright syndrome (MAS) who received 11C-(R)-rolipram whole-body and/or brain PET scans</description>
          </group>
        </group_list>
        <measure>
          <title>Whole Brain Total Distribution Volume (VT)</title>
          <description>Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the brain of patients with McCune-Albright Syndrome (MAS) compared to healthy controls</description>
          <population>Subjects who completed brain scan with 11-C Rolipram</population>
          <units>mL x cm-3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="0.08"/>
                    <measurement group_id="O2" value="0.52" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>MAS Affected Bone SUV AUC(60-120min) at Baseline</title>
        <description>To assess whether uptake in dysplastic bone reflects parent radioligand binding to the enzyme or merely accumulation of radiometabolites</description>
        <time_frame>120 minutes</time_frame>
        <population>Subjects who completed two whole body scans the first with 11-C Rolipram, and the second blocked with Roflumilast</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects With McCune-Albright Syndrome (MAS)</title>
            <description>Subjects with McCune-Albright syndrome (MAS) who received 11C-(R)-rolipram whole-body and/or brain PET scans</description>
          </group>
        </group_list>
        <measure>
          <title>MAS Affected Bone SUV AUC(60-120min) at Baseline</title>
          <description>To assess whether uptake in dysplastic bone reflects parent radioligand binding to the enzyme or merely accumulation of radiometabolites</description>
          <population>Subjects who completed two whole body scans the first with 11-C Rolipram, and the second blocked with Roflumilast</population>
          <units>SUV x min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>MAS Affected Bone SUV AUC(60-120min) - Blocked</title>
        <description>To assess whether uptake in dysplastic bone reflects parent radioligand binding to the enzyme or merely accumulation of radiometabolites</description>
        <time_frame>120 minutes</time_frame>
        <population>Subjects who completed two whole body scans, the first with 11-C Rolipram and the second blocked with Roflumilast</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects With McCune-Albright Syndrome (MAS)</title>
            <description>Subjects with McCune-Albright syndrome (MAS) who received 11C-(R)-rolipram whole-body and/or brain PET scans</description>
          </group>
        </group_list>
        <measure>
          <title>MAS Affected Bone SUV AUC(60-120min) - Blocked</title>
          <description>To assess whether uptake in dysplastic bone reflects parent radioligand binding to the enzyme or merely accumulation of radiometabolites</description>
          <population>Subjects who completed two whole body scans, the first with 11-C Rolipram and the second blocked with Roflumilast</population>
          <units>SUV x min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MAS Affected Bone SUV AUC(60-120min) - for Baseline and Blocked Subjects With MAS</title>
        <description>Determine if PDE4 levels are different in areas of fibrous dysplasia as compared to unaffected bones in patients with MAS</description>
        <time_frame>120 minutes</time_frame>
        <population>The analyses included two group of subjects with MAS: subjects who completed a whole body PET scan with 11-C Rolipram and subjects who completed whole body PET scan after blockade with Roflumilast 500 mcg PO</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects With McCune-Albright Syndrome (MAS)</title>
            <description>Subjects with McCune-Albright syndrome (MAS) who received 11C-(R)-rolipram whole-body and/or brain PET scans</description>
          </group>
        </group_list>
        <measure>
          <title>MAS Affected Bone SUV AUC(60-120min) - for Baseline and Blocked Subjects With MAS</title>
          <description>Determine if PDE4 levels are different in areas of fibrous dysplasia as compared to unaffected bones in patients with MAS</description>
          <population>The analyses included two group of subjects with MAS: subjects who completed a whole body PET scan with 11-C Rolipram and subjects who completed whole body PET scan after blockade with Roflumilast 500 mcg PO</population>
          <units>SUV x min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Normal Bone SUV AUC (60-120min) - for Healthy Controls</title>
        <description>Determine if PDE4 levels are different in areas of fibrous dysplasia as compared to unaffected bones in patients with MAS</description>
        <time_frame>120 minutes after the start of the scan</time_frame>
        <population>Healthy control subjects who completed whole body scan with 11-C Rolipram</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Control</title>
            <description>Healthy control received 11C-(R)-rolipram whole-body and/or brain PET scans</description>
          </group>
        </group_list>
        <measure>
          <title>Normal Bone SUV AUC (60-120min) - for Healthy Controls</title>
          <description>Determine if PDE4 levels are different in areas of fibrous dysplasia as compared to unaffected bones in patients with MAS</description>
          <population>Healthy control subjects who completed whole body scan with 11-C Rolipram</population>
          <units>SUV x min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 day</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Healthy Control</title>
          <description>Healthy control received 11C-(R)-rolipram whole-body and/or brain PET scans</description>
        </group>
        <group group_id="E2">
          <title>Subjects With McCune-Albright Syndrome (MAS)</title>
          <description>Subjects with McCune-Albright syndrome (MAS) received 11C-(R)-rolipram whole-body and/or brain PET scans</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Robert Innis</name_or_title>
      <organization>National Institute of Mental Health</organization>
      <phone>+1 301 693 2979</phone>
      <email>innisr@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

